Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free RNAZ Stock Alerts

TransCode Therapeutics (RNAZ) Competitors

TransCode Therapeutics logo
$4.98 -0.11 (-2.16%)
Closing price 03:59 PM Eastern
Extended Trading
$5.00 +0.02 (+0.38%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RNAZ vs. QNCX, ANEB, KTTA, GRTX, and CTXR

Should you buy TransCode Therapeutics stock or one of its competitors? MarketBeat compares TransCode Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransCode Therapeutics include Quince Therapeutics (QNCX), Anebulo Pharmaceuticals (ANEB), Pasithea Therapeutics (KTTA), Galera Therapeutics (GRTX), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry.

How does TransCode Therapeutics compare to Quince Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

30.8% of Quince Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TransCode Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A
Quince TherapeuticsN/AN/A-$83.98M-$10.62N/A

Quince Therapeutics' return on equity of -372.88% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -50.36%
Quince Therapeutics N/A -372.88%-67.99%

TransCode Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Quince Therapeutics has a consensus target price of $65.00, indicating a potential upside of 6,601.03%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Quince Therapeutics
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71

In the previous week, TransCode Therapeutics had 4 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for TransCode Therapeutics and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.20 beat TransCode Therapeutics' score of 0.25 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransCode Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quince Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Quince Therapeutics beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to Anebulo Pharmaceuticals?

TransCode Therapeutics (NASDAQ:RNAZ) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anebulo Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Anebulo Pharmaceuticals' return on equity of -74.57% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -50.36%
Anebulo Pharmaceuticals N/A -74.57%-68.96%

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A
Anebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/A

TransCode Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, meaning that its share price is 288% less volatile than the broader market.

In the previous week, TransCode Therapeutics had 6 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 6 mentions for TransCode Therapeutics and 0 mentions for Anebulo Pharmaceuticals. TransCode Therapeutics' average media sentiment score of 0.25 beat Anebulo Pharmaceuticals' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TransCode Therapeutics Neutral
Anebulo Pharmaceuticals Neutral

Summary

Anebulo Pharmaceuticals beats TransCode Therapeutics on 6 of the 11 factors compared between the two stocks.

How does TransCode Therapeutics compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Pasithea Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$20.43M-$2.08N/A
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

Pasithea Therapeutics' return on equity of -57.44% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -57.44% -53.61%
TransCode Therapeutics N/A -875.35%-50.36%

In the previous week, TransCode Therapeutics had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 6 mentions for TransCode Therapeutics and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.29 beat TransCode Therapeutics' score of 0.25 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Positive
TransCode Therapeutics Neutral

23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 417.24%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Pasithea Therapeutics beats TransCode Therapeutics on 9 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Galera Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

In the previous week, TransCode Therapeutics had 6 more articles in the media than Galera Therapeutics. MarketBeat recorded 6 mentions for TransCode Therapeutics and 0 mentions for Galera Therapeutics. TransCode Therapeutics' average media sentiment score of 0.25 beat Galera Therapeutics' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
TransCode Therapeutics Neutral

TransCode Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M$0.640.15
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

Galera Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
TransCode Therapeutics N/A -875.35%-50.36%

Summary

TransCode Therapeutics beats Galera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does TransCode Therapeutics compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Citius Pharmaceuticals' return on equity of -61.09% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -61.09% -35.36%
TransCode Therapeutics N/A -875.35%-50.36%

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$37.43M-$2.13N/A
TransCode TherapeuticsN/AN/A-$34.66M-$50.33N/A

In the previous week, TransCode Therapeutics had 4 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 6 mentions for TransCode Therapeutics and 2 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.76 beat TransCode Therapeutics' score of 0.25 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Citius Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
TransCode Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Citius Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 799.44%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats TransCode Therapeutics on 9 of the 13 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAZ vs. The Competition

Export
MetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.84M$2.96B$6.64B$12.06B
Dividend YieldN/A1.71%2.67%5.55%
P/E Ratio-0.1017.7824.7523.76
Price / SalesN/A287.11508.64105.22
Price / CashN/A55.7442.3656.09
Price / Book0.443.8810.476.72
Net Income-$34.66M$75.85M$3.56B$337.35M
7 Day Performance-5.68%-1.46%-1.11%-2.54%
1 Month Performance-31.97%-5.33%1.28%1.42%
1 Year Performance-33.60%15.77%21.20%24.71%

TransCode Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAZ
TransCode Therapeutics
1.0649 of 5 stars		$4.98
-2.2%		N/A-28.7%$4.84MN/AN/A9
QNCX
Quince Therapeutics
1.8884 of 5 stars		$1.01
-4.3%		$65.00
+6,367.7%		-91.5%$16.38MN/AN/A60
ANEB
Anebulo Pharmaceuticals
N/A$0.40
-6.8%		N/A-66.6%$16.34MN/AN/A4
KTTA
Pasithea Therapeutics
3.4412 of 5 stars		$0.64
-0.2%		$3.00
+366.3%		-35.0%$16.05MN/AN/A3
GRTX
Galera Therapeutics
N/A$0.10
-1.0%		N/A+311.8%$16.04MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel